Gene Therapy for Colorectal Liver Metastases Using an Antibody to p21-Ras
Author Information
Author(s): van Etten B, ten Hagen T L M, de Vries M R, Ambagtsheer G, Huet T, Eggermont A M M
Primary Institution: University Hospital Rotterdam-Daniel den Hoed Cancer Centre
Hypothesis
Can an adenoviral vector expressing an intracellular neutralizing antibody to p21-ras effectively inhibit tumor growth in colorectal liver metastases?
Conclusion
Repeated hepatic artery infusion of the Y28 construct resulted in significant tumor growth inhibition in some rats.
Supporting Evidence
- Ras mutations are present in 40–50% of colorectal cancers, suggesting targeting this oncogene may reduce tumor growth.
- Intravenous injection did not result in measurable transfection, while repeated hepatic artery infusion showed significant tumor responses.
- Five times repeated hepatic artery infusion resulted in tumor growth inhibition in three out of eight rats.
Takeaway
This study tested a new way to treat liver cancer by using a special virus to deliver a medicine that stops cancer cells from growing, and it worked for some rats.
Methodology
The study involved in vitro and in vivo experiments using a rat model to evaluate the efficacy of an adenoviral vector delivering a neutralizing antibody to p21-ras.
Potential Biases
Potential bias in the selection of treatment routes and evaluation of outcomes.
Limitations
The study was conducted in a rat model, which may not fully replicate human responses.
Participant Demographics
Male inbred WAG/RIJ rats, weighing 250–300 g.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website